miR-708/LSD1 axis regulates the proliferation and invasion of breast cancer cells

Lin Ma¹,²,a, Shan Ma²,a, Guimei Zhao³, Longqiu Yang⁴, Peng Zhang²,⁎ Qingting Yi²,⁎ & Shuguang Cheng²,⁎

¹Department of Neurology, Shanghai Tongji Hospital, Tongji University, School of Medicine, Shanghai 200065, China
²Department of Oncology, The Center Hospital of Zaozhuang Mining Group, Zaozhuang 277000, China
³Vocational College of Zaozhuang, Zaozhuang 277000, China
⁴Department of Anesthesiology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, 195 Tongbai Road, Zhengzhou City, Henan Province 450007, China

Keywords
Breast cancer, invasion, LSD1, miR-708, proliferation

Abstract
Breast cancer is one of the most common malignant tumors in women worldwide. The microRNAs (miRNAs) are small, noncoding RNAs that regulate various biological processes, including breast cancer. miR-708 played an important role in a variety of cancers. However, its involvement in breast cancer remains largely unclear. In this study, we found that forced the expression of miR-708 in breast cancer cell lines decreased cell proliferation and invasion, whereas inhibition of miR-708 increased cell growth and invasion. miR-708 could directly target the LSD1 3′UTR to downregulate the expression. Further studies suggested that inhibition of LSD1 could phenocopied function of the miR-708 overexpression in MDA-MB-231 cells. Overexpression of LSD1 could counteract the effects of miR-708 on the proliferation and invasion. Taken together, the results indicate that miR-708 may function as a tumor suppressor gene in breast cancer development, and miR-708/LSD1 axis may be a therapeutic intervention in breast cancer in the future.

Introduction
Cancer is a serious threat to human health and social development. According to the report of the International Agency for Research on Cancer (IARC), there were about 1.67 million new cases of breast cancer in the world accounting for 11.88% of all cancer making it become the second most common malignancy worldwide. Breast cancer was regarded as the most serious malignancy that influenced physical and mental health for female [1]. However, the regulatory mechanism of the initiation and the development remain largely unknown.

MicroRNAs (miRNAs), class of endogenous and noncoding RNA molecule, are about 21 nucleotides in length and commonly exist in plants, animals and virus genomes. It can directly bind to the 3′-untranslated region (3′-UTR) of target transcripts and degrade target mRNA level or suppress its translation in many kinds of biological processes [2–4], especially in cancer cell proliferation, migration, differentiation, and many other
biological functions [5]. The discovery of miRNAs has created a new area of cancer research and uncovered the complicity of cancer biology [6]. Iorio et al. firstly reported in 2005 that 29 miRNAs were significantly altered in breast tumor tissues compared to normal breast tissues. Recently, more and more miRNAs were found to be involved in the progression and development of breast carcinoma [7]. MicroRNA-708 (miR-708), a newly discovered miRNA, has proved to be critical in the regulation of different kinds of tumor. Aberrant miR-708 expression is closely associated with cell proliferation, migration, invasion, apoptosis, and patient prognosis in renal cell carcinoma, lung adenocarcinoma, hepatocellular carcinoma, ovarian carcinoma, bladder carcinoma, and prostate carcinoma [8–13]. However, few studies have paid attention to the functions of miR-708 in breast carcinoma and the molecular regulation mechanism of miR-708 in breast carcinoma still remains largely unknown.

Lysine-specific histone demethylase 1 (LSD1) is a kind of histone demethylase which specifically demethylates mono- and dimethylated lysine 4 and lysine 9 of histone H3 [14]. LSD1 is necessary for mammalian development and is involved in various biological processes. Recent studies have demonstrated that LSD1, located in the nucleus, regulated gene transcription [15]. LSD1 has been closely linked to embryonic development and tumorigenesis [16]. Moreover, many evidences identified its pivotal role in breast carcinoma and suggested a possible molecular mechanism to some extent [17–26]. Nevertheless, as a novel and important epigenetic regulator, the further mechanism of the regulation of LSD1 and the upregulator of LSD1 still remain largely unknown.

In this study, we reported that forced expression of miR-708 significantly suppressed MDA-MB-231 proliferation and invasion, whereas inhibition of miR-708 promoted MDA-MB-231 proliferation and invasion. Furthermore, we identified LSD1 as a potential target gene of miR-708. siRNA-mediated knockdown of LSD1 could partially mimic the effects of miR-708. Overexpression of LSD1 could abrogate miR-708-inhibited cell proliferation and invasion.

**Material and Methods**

**Cell culture**

The human breast carcinoma cell line MDA-MB-231 was purchased from Cell Bank at Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Thermo, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, USA), 100 units/ml streptomycin, and 100 units/ml penicillin.

**Plasmid and transfection**

The 3’UTR segment of wild-type LSD1 mRNA, which possessed the binding site for miR-708, was amplified and cloned into the pGL3 vector. The mutant miRNA-binding sites were obtained by replacing the miRNA-binding site sequence with miRNA seed sequences using the QuickChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). The LSD1 expression vector was performed by cloning LSD1-coding sequence into Fugw. The miR-708 precursor, precursor control, inhibitor, and inhibitor control were purchased from Ribobio (Guangzhou, China). Cells were harvested or suspended for RT-PCR, western blotting, and other experiments mentioned in this paper.

**RT-PCR for miRNA and mRNA expression**

To measure the expression of miRNAs, 2 μg total RNA was used to synthesize cDNA. Expression values were normalized to the control endogenous small RNA U6. To detect mRNA expression, 500 ng of total RNA was used to synthesize cDNA. Primer sequences for LSD1 was listed as follows: GAPDH (forward: 5'-CTTGTGCTACACTGAGCACC-3; reverse: 5'-AAAGTGGTCAAGGGCCAATG-3), LSD1 (forward: 5'-GGCTTGAGGCTGACGTGCA-3; reverse: 5'-TGACCACATTGATGATCC-3).

**Western blotting**

Proteins were separated by SDS-PAGE and transferred to membranes. Primary antibodies used in this study were listed as follows: anti-GAPDH (ab97626, Abcam, Cambridge, MA, USA), anti-LSD1 (ab17721, Abcam, Cambridge, MA, USA). Signals were detected by using enhanced chemiluminescence (ECL) (Thermo, USA).

**Cell proliferation assay**

Cells were transfected with precursor or inhibitor for 48 h and then seeded in 96-well plates at a density of 3.5 × 10³ cells/well. Cell counts were conducted after 24 h, 48 h, and 72 h. Cell counting Kit-8 solution was added at each time point for 1 h at 37°C and measured the absorbance at 490 nm with a spectrophotometer.

**Cell invasion assay**

Cell invasion assay was performed by using transwell inserts with 8.0 μm pores in 24-well plates. Transwell filter was coated with Matrigel to mimic the microenvironment. Cells were suspended in medium without serum. In the
miR-708/LSD1 Axis in Breast Cancer Cells

L. Ma et al.

A. Relative level of miRNA-708

B. Invasion of cells per field

C. Cell images

D. Absorbance 490 nm

E. Cell images

F. Absorbance 490 nm

G. Cell images
**Results**

miR-708 inhibited tumor cell proliferation and invasion

To determine the role of miR-708 in breast cancer cells, we use MDA-MB-231, a highly malignant degree cell line and a useful tool for studying tumorigenesis mechanism and biology [27, 28]. Transient transfection of miR-708 precursor resulted in miR-708 overexpression as validated by RT-PCR (Fig. 1A). Interestingly, we observed apparent decrease in growth rate when miR-708 was upregulated (Fig. 1C). miR-708-inhibitor cell grew significantly slower than the control cell line (Fig. 1G). Next, we quantified cell growth rate by using CCK8 assay and found that miR-708 had a negative correlation with cell proliferation (Fig. 1D, F). Moreover, our results found that miR-708 was involved in cell invasion of breast cancer. Overexpression of miR-708 decreased MDA-MB-231 invasion, whereas inhibition of miR-708 promoted MDA-MB-231 invasion (Fig. 1B, E).
miR-708 specifically regulated LSD1 expression in breast cancer

To identify a target gene of miR-708, TargetScan, Pictar, and miRanda were used to search for mRNAs that interact with miR-708. We focused on LSD1, inspired not only by the program prediction, but also by the importance of LSD1 in breast cancer. The predicted binding site between LSD1 and miR-708 was showed in Figure 2A. Then, we performed luciferase reporter

**Figure 3.** LSD1 inhibition partially phenocopies miR-708 overexpression, whereas overexpression of LSD1 has opposite effects. (A). The mRNA level of LSD1 was reduced by siRNA-LSD1-1 or siRNA-LSD1-2 which specifically target LSD1. **P < 0.01. (B). Inhibition of LSD1 upregulated MDA-MB-231 cells invasion. *P < 0.05, **P < 0.01. (C). MDA-MB-231 cells grew much faster as a result of LSD1 inhibition. (D). Proliferation of MDA-MB-231 cells was analyzed using CCK-8 assay. **P < 0.01. (E). LSD1 expression was upregulated with the treatment of LSD1 lentivirus infection. **P < 0.01. (F). Lentivirus infection efficiency was confirmed at 72 h by using RT-PCR. **P < 0.01. (G). Cells grew much slower with the treatment of LSD1 lentivirus infection. (H). CCK-8 assay was performed to evaluate the proliferation rate of MDA-MB-231 cells with the treatment of LSD1 lentivirus infection. **P < 0.01. *P < 0.05.
assay to determine whether miR-708 can target the 3′UTR of LSD1. Wide type and mutant 3′UTR reporter was generated and transfected into 293FT cells with pre-miR-708. Our results suggested that the luciferase activity of WT-3′UTR was obviously suppressed by pre-miR-708 (Fig. 2B). Then we found endogenous LSD1 was regulated by pre-miR-708. Both mRNA and protein level of LSD1 were decreased after miR-708 transfection (Fig. 2C).

**LSD1 was critically involved in the regulation of proliferation and invasion in breast cancer**

In view of the observed functions of miR-708 on proliferation and invasion, we tried to find whether miR-708 regulated cancer cell through LSD1. Two different LSD1 siRNA were transfected into cancer cell. RT-PCR was conducted to confirm the silence effects of siRNA (Fig. 3A). The data revealed that, as expected, LSD1 siRNA-transfected cells inhibited cell invasion, which is consistent with the effects of miR-708 (Fig. 3B). Moreover, treatment with LSD1 siRNA also resulted in decreased proliferation, which is similar to the phenomenon observed upon miR-708 overexpression in cancer cells (Fig. 3C–D). LSD1 lentivirus vector was constructed and expression efficiency was measured by RT-PCR (Fig. 3E). Overexpression of LSD1 could significantly enhance MDA-MB-231 proliferation and invasion (Fig. 3F–H).

**miR-708 inhibited proliferation and invasion by inhibiting LSD1**

To determine whether the miR-708-LSD1 interaction is necessary for breast cancer cell, MDA-MB-231 was infected with lentivirus vector that overexpressed LSD1. The cells were subsequently transfected with pre-miR-708. LSD1 expression in different groups was showed in Figure 4A. We found that overexpression of LSD1 could partially counteract miR-708-decreased invasion (Fig. 4B).
Moreover, overexpression of LSD1 could partially abrogated miR-708-induced proliferation (Fig. 4C–D).

**Discussion**

Preventing tumor growth and invasion has been the most challenging problem in the treatments for breast cancer. Our data showed that overexpression of miR-708 significantly decreased MDA-MB-231 invasion, whereas inhibition of miR-708 increased MDA-MB-231 invasion. Previous studies have revealed the important role of miR-708 in regulating cancer cell migration and invasion in other malignancies. miR-708 expression was decreased in human renal cell carcinoma (RCC) specimens and downregulation of miR-708 in RCC cell lines increased cancer cell invasion, which is similar to our finding [8]. Besides, overexpression of miR-708 inhibited cell invasion in the human glioblastoma cell lines A172 and T98G [29]. However, downregulation of miR-708 in hepatocellular cell suppressed tumor invasion and migration [13]. miR-708 overexpression in lung cancer cell lines increased cell invasion by twofold compared with the control [9]. This suggests that miR-708 have divergent functions in different microenvironments. Additionally, we found that miR-708 had a negative relation with cell proliferation in breast cancer. Inhibition of miR-708 in MDA-MB-231 could enhance cell proliferation, whereas restoration of miR-708 with mimics could reduce cell proliferation. Several studies have reported on the dysregulation of miR-708 in cell proliferation [9, 29, 30]. Collectively, our results demonstrated that miR-708 function as an antitumor factor in breast cancer.

Up to now, an increasing number of miRNAs have been reported to be closely related to breast cancer. miR-10b promoted breast cancer cell migration and invasion by inhibiting HOXD10 protein synthesis [31]. miR-21 overexpression in breast cancer is causally linked to advanced clinical stage, lymph node metastasis, and patient poor prognosis. Moreover, miR-21 silencing in breast cancer cells suppressed cell growth and tumor suppressor protein Programmed Cell Death 4 (PDCD4) is a functionally important target for miR-21 in breast cancer [32, 33]. MiR-155 served as an oncomiR in breast cancer in promoting the proliferation of breast cancer cells [34]. Besides miRNAs mentioned above, miR-451, miR-146, miR-221/222, and other miRNAs were also confirmed to be closely associated with breast cancer [35–37].

In breast cancer cell line MDA-MB-231, using western blotting and luciferase assay, we found miR-708 directly binds to the 3′utr region of LSD1, a critical gene that has been widely verified to be involved in breast cancer metastasis [19, 22, 23, 38]. Our data showed that siRNA-mediated silencing of LSD1 could partially mimic the effects of miR-708, whereas restoration of LSD1 could counteract the effects of miR-708 in MDA-MB-231. The results demonstrated that miR-708 and LSD1 closely interact in regulating growth and invasion of breast cancer cells.

A few of studies are currently ongoing to make a foundation for introducing miRNAs in clinical practice. A phase I trial is underway in United Stated to test MRX34 (Mirna Therapeutics, Inc., Austin, TX, USA) as the first miRNA replacement therapy in human. Given that the role of miR-708/LSD1 as genomic regulators in breast cancer development and metastasis, miR-708 might be applied to treatment for breast cancer.

In conclusion, our findings showed that miR-708 might serve as an antioncogene by directly targeting LSD1, through promoting cell growth and cell invasion. Hence, it suggests the potential application of miR-708/LSD1 axis for treatment of breast cancer in the future.

**Conflict of Interest**

None declared.

**References**

1. Ferlay, J., I. Soerjomataram, R. Dikshit, et al. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer Suppl. 136:E359–E386.
2. Hu, J., C. Chen, Q. Liu, et al. 2015. The role of the miR-31/FH1 pathway in TGF-beta-induced liver fibrosis. Clin. Sci. 129:305–317.
3. Lee, R. C., R. L. Feinbaum, and V. Ambros. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854.
4. Liu, Q., G. Wang, Y. Chen, G. Li, D. Yang, and J. Kang. 2014. A miR-590/Acrv2a/Rad51b axis regulates DNA damage repair during mESC proliferation. Stem Cell Rep. 3:1103–1117.
5. Croce, C. M. 2009. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10:704–714.
6. Calin, G. A., and C. M. Croce. 2006. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 66:7390–7394.
7. Mulrane, L., S. F. McGee, W. M. Gallagher, and D. P. O’Connor. 2013. miRNA dysregulation in breast cancer. Cancer Res. 73:6554–6562.
8. Saini, S., S. Yamamura, S. Majid, et al. 2011. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res. 71:6208–6219.
9. Jang, J. S., H. S. Jeon, Z. Sun, et al. 2012. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin. Cancer Res. 18:3658–3667.

10. Song, T., X. Zhang, L. Zhang, et al. 2013. miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2. J. Cancer Res. Clin. Oncol. 139:1189–1198.

11. Saini, S., S. Majid, V. Shahryari, et al. 2012. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res. 72:3618–3630.

12. Yang, J., J. Wei, Y. Wu, et al. 2015. Metformin induces ER stress-dependent apoptosis through miR-708-5p/NNAT pathway in prostate cancer. Oncogene 4:e158.

13. Li, G., F. Yang, H. Xu, Z. Yue, X. Fang, and J. Liu. 2015. MicroRNA-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration. Biomed. Pharmacother. 73:154–159.

14. Shi, Y., F. Lan, C. Matson, et al. 2004. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941–953.

15. Metzger, E., M. Wissmann, N. Yin, et al. 2005. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436–439.

16. Hayami, S., J. D. Kelly, H. S. Cho, et al. 2011. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer Suppl. 128:574–586.

17. Bennani-Baiti, I. M. 2012. Integration of ERalpha-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer. Breast Cancer Res. 14:112.

18. Derr, R. S., A. Q. van Hoesel, A. Benard, et al. 2014. High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC Cancer 14:604.

19. Li, Q., L. Shi, B. Gui, et al. 2011. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 71:6899–6908.

20. Nagasawa, S., A. S. Sedukhina, Y. Nakagawa, et al. 2015. LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition. PLoS ONE 10:e0118002.

21. Ombrà, M. N., A. Di Santi, C. Abbondanza, A. Migliaccio, E. V. Avvedimento, and B. Perillo. 2013. Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA. Biochim. Biophys. Acta 1829:480–486.

22. Vasilatos, S. N., T. A. Katz, S. Oesterreich, Y. Wan, N. E. Davidson, and Y. Huang. 2013. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis 34:1196–1207.

23. Wang, Y., H. Zhang, Y. Chen, et al. 2009. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138:660–672.

24. Wu, Y., Y. Yang, X. H. Yang, et al. 2013. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep. 5:224–236.

25. Yu, S. E., and Y. K. Jang. 2012. The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells. Biochem. Biophys. Res. Commun. 427:336–342.

26. Zhu, Q., Y. Huang, L. J. Marton, P. M. Woster, N. E. Davidson, and R. A. Jr Casero. 2012. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids 42:887–898.

27. Mertens-Talcott, S. U., S. Chintiharlapalli, X. Li, and S. Safe. 2007. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 67:11001–11011.

28. Yoneda, T., P. J. Williams, T. Hiraga, M. Niewolna, and R. Nishimura. 2001. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Miner. Res. 16:1486–1495.

29. Guo, P., J. Lan, J. Ge, Q. Nie, Q. Mao, and Y. Qiu. 2013. miR-708 acts as a tumor suppressor in human glioblastoma cells. Oncol. Rep. 30:870–876.

30. Lei, S. L., H. Zhao, H. L. Yao, et al. 2014. Regulatory roles of microRNA-708 and microRNA-31 in proliferation, apoptosis and invasion of colorectal cancer cells. Oncol. Lett. 8:1768–1774.

31. Ma, L., J. Teruya-Feldstein, and R. A. Weinberg. 2007. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682–688.

32. Frankel, L. B., N. R. Christoffersen, A. Jacobsen, M. Lindow, A. Krogh, and A. H. Lund. 2008. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 283:1026–1033.

33. Yan, L. X., X. F. Huang, Q. Shao, et al. 2008. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14:2348–2360.

34. Jiang, S. A., H. W. Zhang, M. H. Lu, et al. 2010. MicroRNA-155 Functions as an OncomiR in Breast
Cancer by Targeting the Suppressor of Cytokine Signaling 1 Gene. Cancer Res. 70:3119–3127.

35. Kovalchuk, O., J. Filkowski, J. Meservy, et al. 2008. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7:2152–2159.

36. Bhaumik, D., G. K. Scott, S. Schokrpur, C. K. Patil, J. Campisi, and C. C. Benz. 2008. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27:5643–5647.

37. Zhao, J. J., J. Lin, H. Yang, et al. 2008. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283:31079–31086.

38. Lim, S., A. Janzer, A. Becker, et al. 2010. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31:512–520.

Supporting Information

Additional supporting information may be found in the online version of this article:

Figure S1. Related to the Figure 1 miR-708 has a positive correlation with breast cancer cells growth and invasion.

Figure S2. Related to the Figure 3 LSD1 regulates the proliferation and invasion of T47D cells.

Figure S3. Related to the Figure 4 LSD1 directly blocked the function of miR-708 on inhibiting proliferation and invasion of T47D cells.